Welcome to Idorsia

Annual General
Meeting 2019

Our AGM 2019 took place on Friday May 3, 2019.

Idorsia announces
financial results
as of March 31, 2019

We've made
outstanding
progress
in 2018 -
interested to
learn more?

Our key assets have
the potential to
transform treatment in
the target indications...

Read about how our IT department
achieved operational independence
ahead of schedule...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s future success entirely depends on our people.

Idorsia's development compounds target a number of different diseases.

13 Jun 2019	Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
03 May 2019	Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved
18 Apr 2019	Idorsia announces financial results for the first quarter 2019

Event	When
Half-Year 2019 Financial Results reporting*	July 23, 2019
Nine-months 2019 Financial Results reporting*	October 22, 2019
Full-Year 2019 Financial Results reporting*	February 6, 2020

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 10:50:30 CET

21.06 CHF

+0.14 (+0.67 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland